Form 4: Fairmount Funds Management Acquires Stock Options in Jade Biosciences

Fairmount Funds Management, along with related entities and individuals, reports acquiring stock options in Jade Biosciences, Inc.

Summary

• Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Tomas Kiselak, and Peter Harwin filed a Form 4 regarding changes in beneficial ownership of Jade Biosciences, Inc. securities.
• The earliest transaction date reported is April 29, 2025.
• A stock option (right to buy) 23,017 shares of Jade Biosciences common stock at an exercise price of $10.14 was acquired.
• The option vests on the earlier of April 29, 2026, or the date of the next annual meeting of the Issuer's stockholders, subject to continued service.
• Tomas Kiselak disclaims beneficial ownership of the option and underlying common stock, as he holds the option for investment vehicles managed by Fairmount Funds Management LLC.
• Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.
• Fairmount, Fairmount Healthcare Fund II LP and Fairmount Healthcare Co-Invest IV L.P. may each be deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is a manager of Fairmount.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating insider activity. The acquisition of options could be seen as mildly positive, but the disclaimers of beneficial ownership introduce some complexity.

Positives

• The acquisition of stock options by Fairmount Funds Management could be seen as a positive signal, indicating confidence in Jade Biosciences' future prospects.

Risks

• Tomas Kiselak disclaims beneficial ownership, which could indicate a complex ownership structure.
• Fairmount's disclaimer of beneficial ownership, except for pecuniary interest, may suggest limited direct control or influence.

Future Outlook

The document does not contain explicit forward-looking statements, but the acquisition of stock options suggests a potential long-term interest in Jade Biosciences.

Industry Context

Form 4 filings are standard disclosures for insiders and significant shareholders, providing transparency into their transactions in the company's securities. This filing indicates activity by a major shareholder, Fairmount Funds Management, which is relevant to investors tracking ownership changes.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for company insiders and major shareholders in the US, similar to insider transaction reporting requirements in other developed markets.
• The vesting schedule of the options (one year) is relatively standard for executive compensation packages.
• The size of the option grant (23,017 shares) should be compared to the total outstanding shares of Jade Biosciences to determine its significance.

Stakeholder Impact

• Shareholders may view the acquisition of stock options by Fairmount Funds Management as a positive signal.
• The vesting schedule of the options incentivizes continued service from the recipient.

Key Dates

Keywords

Form 4, beneficial ownership, stock options, Jade Biosciences, Fairmount Funds Management, Kiselak, Harwin, director, 10% Owner